-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200

Benzinga·07/13/2026 16:26:45
语音播报
Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $155 to $200.